NCT01816984 · REGISTRY CONDITION SEARCH

PI3K Inhibitor BKM120 and Cetuximab in Treating Patients With Recurrent or Metastatic Head and Neck Cancer

Found through the registry condition index, not selected as a treatment recommendation. This discovery collection was restricted to studies with posted results.

Phase: PHASE1, PHASE2
Status at capture: COMPLETED
Registry last update: 2021-10-05

This pilot randomized phase I/II trial studies the side effects and best dose of PI3K inhibitor BKM120 when given together with cetuximab and to see how well it works in treating patients with recurrent or metastatic head and neck cancer. PI3K inhibitor BKM120 may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Monoclonal antibodies, such as cetuximab, can block tumor growth in different ways. Some block the ability of tumors to grow and spread. Others find tumor cells and help kill them or carry tumor-killing substances to them. Giving PI3K inhibitor BKM120 together with cetuximab may kill more tumor cells

Open the original ClinicalTrials.gov record → · Download preserved record

What did the study report?

Outcomes, safety and baseline populations are separate source sections. Quality-of-life measures appear under their original outcome titles.

flow

Participant flow

→

baseline

Baseline characteristics

→

outcome · POSTED

Compensatory Signaling/Feedback Loop Signaling Evaluated by Measurement of Phosphorylated (p)-EGFR

→

outcome · POSTED

Maximum Tolerated Dose (MTD)

→

outcome · POSTED

Apoptosis Induction

→

outcome · POSTED

Response Rate Assessed Using RECIST

→

outcome · POSTED

Response Rate in Patients With Prior EGFR Failure Assessed Using RECIST

→

outcome · POSTED

Tumor Shrinkage

→

outcome · POSTED

Overall Survival

→

outcome · POSTED

Progression Free Survival

→

adverse events

Adverse events

→

more info

Limitations, agreements, and source contact

→

Who could take part

eligibility Criteria: Inclusion Criteria: * Histologically / cytologically confirmed diagnosis of squamous cell carcinoma of head and neck origin not amenable to curative intent therapy; both human papillomavirus (HPV)(+) and HPV(-) tumors are eligible; tumors (squamous histology) of unknown primary that are clearly related to the head and neck area are eligible * Presence of measurable lesions (RECIST V1.1) * Mandatory tumor biopsy/biopsies in accessible tumors; for inaccessible tumors availability of tissue is required: \>= 10 tumor containing formalin-fixed paraffin-embedded (FFPE) slides/sections * Progressive disease after exposure to a platinating agent (e.g. cisplatin or carboplatin) in a prior line of therapy, or documented intolerance to such an agent * Eastern Cooperative Oncology Group (ECOG) performance status =\< 2 * No more than two lines of prior cytotoxic chemotherapy in the recurrent/metastatic (palliative intent) treatment setting * Prior use of cetuximab or another epidermal growth factor receptor (EGFR) inhibitor is allowable and if used as a single agent should not be considered as a cytotoxic chemotherapy * Patients must have at least one site of measurable disease (if applicable) (per RECIST for solid tumors or the appropriate disease classification/criteria for the target population) * Absolute neutrophil count (ANC) \>= 1.5 x 10\^9/L * Platelets \>= 100 x 10\^9/L * Hemoglobin (Hb) \> 9 g/dL * Total calcium (corrected for serum albumin) within normal limits * Magnesium \>= the lower limit of normal for the institution * Potassium within normal limits for the institution * Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) within 1.5 x normal range (or =\< 3.0 x upper limit of normal \[ULN\] if liver metastases are present) * Serum bilirubin within normal range (or =\< 1.5 x ULN if liver metastases are present; or total bilirubin =\< 3.0 x ULN with direct bilirubin within normal range in patients with well documented Gilbert syndrome) * Serum creatinine =\< 1.5 x ULN or 24-hour clearance \>= 50 mL/min * Serum amylase =\< ULN * Serum lipase =\< ULN * Fasting plasma glucose =\< 120 mg/dL (6.7 mmol/L) * Negative serum pregnancy test within 72 hours before starting study treatment in women with childbearing potential * Signed informed consent * International normalized ratio (INR) =\< 2.5 Exclusion Criteria: * Patients who have received prior treatment with a P13K inhibitor * No available tumor material for correlative studies * Patients with a known hypersensitivity to BKM120 or to its excipients, or hypersensitivity to cetuximab * More than two prior lines of cytotoxic chemotherapy in the recurrent/metastatic disease setting (palliative treatment intent)(excluding single agent use of an EGFR inhibitor) * Patients with untreated brain metastases are excluded; however, patients with treated brain metastases are eligible if they are \> 4 weeks from therapy completion (including radiation and/or surgery), are clinically stable at the time of study entry and are not receiving corticosteroid therapy at the time of study entry * Patients with acute or chronic liver, renal disease or pancreatitis * Patients with the following mood disorders as judged by the Investigator or a psychiatrist, or as a result of patient's mood assessment questionnaire (treating physician to decide on whether to administer questionnaire): * Medically documented history of or active major depressive episode, bipolar disorder (I or II), obsessive-compulsive disorder, schizophrenia, a history of suicidal attempt or ideation, or homicidal ideation (immediate risk of doing harm to others) * \>= Common Terminology Criteria for Adverse Events (CTCAE) version 4 (v4) grade 3 anxiety * Meets the cut-off score of \>= 10 in the Patient Health Questionnaire 9 (PHQ-9) or a cut-off of \>= 15 in the Generalized Anxiety Disorder 7 (GAD-7) mood scale, respectively, or selects a positive response of "1, 2, or 3" to question number 9 regarding potential for suicidal thoughts in the PHQ-9 (independent of the total score of the PHQ-9) * Patients with diarrhea \>= CTCAE v4 grade 2 * Patient has active cardiac disease including any of the following: * History of clinically significant heart failure (previously assessed) with a left ventricular ejection fraction (LVEF) of \< 50% as determined by multiple grated acquisition (MUGA) scan or echocardiogram (ECHO) * Corrected QT (QTc) \> 480 msec on screening electrocardiogram (ECG) (using the Fridericia QT correction \[QTcF\] formula) * Angina pectoris that requires the use of anti-anginal medication * Ventricular arrhythmias except for benign premature ventricular contractions * Supraventricular and nodal arrhythmias requiring a pacemaker or not controlled with medication * Conduction abnormality requiring a pacemaker * Valvular disease with document compromise in cardiac function * Symptomatic pericarditis * Patient has a history of cardiac dysfunction including any of the following: * Myocardial infraction within the last 6 months, documented by persistent elevated cardiac enzymes or persistent regional wall abnormalities on assessment of LVEF function * History of documented congestive heart failure (New York Heart Association functional classification III-IV) * Documented cardiomyopathy * Patient has poorly controlled diabetes mellitus or steroid-induced diabetes mellitus (hemoglobin A1C \[HbA1C\] \> 7.5%) * Patients with any history of hyperglycemia (elevated blood glucose level on blood chemistries) should be considered for initiation of Metformin treatment (500mg, PO, twice daily) prior to starting BKM120 * Other concurrent severe and/or uncontrolled concomitant medical conditions (e.g., active or uncontrolled infection) that could cause unacceptable safety risks or compromise compliance with the protocol * Significant symptomatic deterioration of lung function; if clinically indicated, pulmonary function tests including measures of predicted lung volumes, diffusing capacity of the lung for carbon monoxide (DLCO), oxygen (O2) saturation at rest on room air should be considered to exclude pneumonitis or pulmonary infiltrates * Impairment of gastrointestinal (GI) function or GI disease that may significantly alter the absorption of BKM120 (e.g., ulcerative diseases, uncontrolled nausea, vomiting, diarrhea, malabsorption syndrome, or small bowel resection); patients with unresolved diarrhea will be excluded as previously indicated * Patients who have been treated with any hematopoietic colony-stimulating growth factors (e.g., filgrastim \[G-CSF\], sargramostim \[GM-CSF\]) =\< 2 weeks prior to starting study drug; erythropoietin or darbepoetin therapy, if initiated at least 2 weeks prior to enrollment, may be continued * Patients who are currently receiving treatment with medication with a known risk to prolong the QT interval or inducing Torsades de Pointes and the treatment cannot either be discontinued or switched to a different medication prior to starting study drug * Patients receiving chronic treatment with steroids or another immunosuppressive agent other than specified in exclusion criterion #4 * Note: Topical applications (e.g. rash), inhaled sprays (e.g. obstructive airways diseases), eye drops or local injections (e.g. intra-articular) are allowed; patients with previously treated brain metastases, who are on stable low dose corticosteroids treatment (eg. dexamethasone 2 mg/day, prednisolone 10 mg/day) for at least 14 days before start of study treatment are eligible * Patients who have taken herbal medications and certain fruits within 7 days prior to starting study drug; herbal medications include, but are not limited to St. John's wort, Kava, ephedra (ma huang), gingko biloba, dehydroepiandrosterone (DHEA), yohimbe, saw palmetto, and ginseng; fruits include the cytochrome P450, family 3, subfamily A (CYP3A) inhibitors Seville oranges, grapefruit, pummelos, or exotic citrus fruits * Patients who are currently treated with drugs known to be moderate and strong inhibitors or inducers of isoenzyme CYP3A, and the treatment cannot be discontinued or switched to a different medication prior to starting study drug * Patients who have received chemotherapy or targeted anticancer therapy =\< 4 weeks (6 weeks for nitrosourea, antibodies or mitomycin-C) prior to starting study drug must recover to a grade 1 before starting the trial * Patients who have received any continuous or intermittent small molecule therapeutics (excluding monoclonal antibodies) =\< 5 effective half lives prior to starting study drug or who have not recovered from side effects of such therapy; typically a \>= 2 week interval since completion of prior therapy is recommended and 4 weeks for monoclonal antibodies * Patients who have received wide field radiotherapy =\< 4 weeks or limited field radiation for palliation =\< 2 weeks prior to starting study drug or who have not recovered from side effects of such therapy * Patients who have undergone major surgery =\< 2 weeks prior to starting study drug or who have not recovered from side effects of such therapy * Patients who are currently taking therapeutic doses of warfarin sodium or any other Coumadin-derivative anticoagulant * Women who are pregnant or breast-feeding or adults of reproductive potential not employing an effective method of birth control; double barrier contraceptives must be used through the trial by both sexes; oral, implantable, or injectable contraceptives may be affected by cytochrome P450 interactions, and are therefore not considered effective for this study; women of child-bearing potential, defined as sexually mature women who have not undergone a hysterectomy or who have not been naturally postmenopausal for at least 12 consecutive months (i.e., who has had menses any time in the preceding 12 consecutive months), must have a negative serum pregnancy test =\< 72 hours prior to initiating treatment * Known diagnosis of human immunodeficiency virus (HIV) infection unless patient is fully immunocompetent (cluster of differentiation 4 \[CD4\] \> 200) and patient is not taking antiretroviral therapy * History of another malignancy within 3 years, except cured basal cell carcinoma of the skin or excised carcinoma in situ of the cervix, or any tumor that is after clearing with the principal investigator (PI) clearly not considered to have impact on prognosis * Patient is unable or unwilling to abide by the study protocol or cooperate fully with the investigator
healthy Volunteers: false
minimum Age: 18 Years
sex: ALL
std Ages: ADULT
OLDER_ADULT

Treatment arms and interventions

arm Groups

description
Patients receive PI3K inhibitor BKM120 PO QD 100 mg/day on days -7 to 0. Patients complete 1 week washout. 3 patients receive BKM120 PO 80mg / day and cetuximab 500 mg IV /14 days and after dose escalation, 9 patients receive BKM120 PO 100mg / day and cetuximab 500 mg IV /14 days thereafter. All patients receive PI3K inhibitor BKM120 PO QD day on days 1-28 and cetuximab IV over 60-120 minutes on days 1 and 15. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
intervention Names
Drug: PI3K inhibitor BKM120
Biological: cetuximab
label
Arm I (BKM120 PO and cetuximab 500 mg IV 14 days)
type
EXPERIMENTAL

interventions

arm Group Labels
Arm I (BKM120 PO and cetuximab 500 mg IV 14 days)
description
Given PO
name
PI3K inhibitor BKM120
other Names
BKM120
PI3K_Inhibitor_BKM120
type
DRUG
arm Group Labels
Arm I (BKM120 PO and cetuximab 500 mg IV 14 days)
description
Given IV
name
cetuximab
other Names
C225
C225 monoclonal antibody
IMC-C225
MOAB C225
monoclonal antibody C225
type
BIOLOGICAL

Study design

allocation

intervention Model

SINGLE_GROUP

masking Info

masking: NONE

primary Purpose

TREATMENT

Enrollment

count: 12
type: ACTUAL

Registered outcome plans (not posted results)

primary Outcomes

description
Performed using snap frozen tissue samples using the well-established PamGene Kinase array platform available in the Salgia/Seiwert laboratories.
measure
Compensatory Signaling/Feedback Loop Signaling Evaluated by Measurement of Phosphorylated (p)-EGFR
time Frame
1 week
description
Maximum tolerated dose (MTD) is defined as the dose level preceding the dose in which greater than or equal to 2 out of 3-6 patients experience a dose limiting toxicity (DLT) assessed using CTCAE v4
measure
Maximum Tolerated Dose (MTD)
time Frame
28 days

secondary Outcomes

description
Measured by Terminal deoxynucleotidyl transferase dUTP nick end labeling (TUNEL) assay on Formalin-Fixed, Paraffin-Embedded (FFPE) sections in a descriptive manner.
measure
Apoptosis Induction
time Frame
Up to 28 days
description
Percentage of patients whose cancer shrinks or disappears after treatment.
measure
Response Rate Assessed Using RECIST
time Frame
Up to 28 days
description
Percentage of patients with prior EGFR failure assessed using RECIST whose cancer shrinks or disappears after treatment.
measure
Response Rate in Patients With Prior EGFR Failure Assessed Using RECIST
time Frame
Up to 28 days
description
Tumor shrinkage will be visualized as a waterfall plot for graphical (qualitative) comparison.
measure
Tumor Shrinkage
time Frame
Up to 28 days
description
Overall survival is defined as the time from study initiation to death due to any reason.
measure
Overall Survival
time Frame
4 years and 3 months
description
Progression free survival is defined as the time from study initiation to first evidence of progression of disease.
measure
Progression Free Survival
time Frame
4 years and 3 months

Full study description

brief Summary: This pilot randomized phase I/II trial studies the side effects and best dose of PI3K inhibitor BKM120 when given together with cetuximab and to see how well it works in treating patients with recurrent or metastatic head and neck cancer. PI3K inhibitor BKM120 may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Monoclonal antibodies, such as cetuximab, can block tumor growth in different ways. Some block the ability of tumors to grow and spread. Others find tumor cells and help kill them or carry tumor-killing substances to them. Giving PI3K inhibitor BKM120 together with cetuximab may kill more tumor cells
detailed Description: PRIMARY OBJECTIVES: I. Induction of compensatory signaling/feedback loop signaling after one week of BKM120 (PI3K inhibitor BKM120) (run-in) compared to patients not treated with BKM120. II. Safety and tolerability of combined treatment with BKM120 and cetuximab. SECONDARY OBJECTIVES: I. Induction of apoptosis after one week of BKM120 (run-in) compared to patients not treated with BKM. II. Tumor shrinkage (based Response Evaluation Criteria in Solid Tumors \[RECIST\] version 1.1 \[V1.1\] measurements) in patients treated with combination. III. Response rate (based RECIST V1.1 measurements) in patients treated with combination. IV. Overall survival. V. Progression free survival. OUTLINE: This is a phase I, dose-escalation study of PI3K inhibitor BKM120, followed by a phase II study. RUN-IN-PERIOD: Patients are randomized to 1 of 2 treatment arms. ARM I: Patients receive PI3K inhibitor BKM120 orally (PO) once daily (QD) on days -7 to 0. Patients complete 1 week washout before dose escalation. ARM II: Patients receive no treatment on days -7 to 0. All patients receive PI3K inhibitor BKM120 PO QD on days 1-28 and cetuximab intravenously (IV) over 60-120 minutes on days 1 and 15. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity. After completion of study treatment, patients are followed up for 28 days.

Source references

Source notices and limitations

Discovery and provenance

release id
ctgov-registry-1336d216cbd1bbff780dac70
edge id
nct-edge-2206846920cc9860307e
requested nct id
NCT01816984
primary nct id
NCT01816984
source kind
ctgov_condition_query
source url
https://clinicaltrials.gov/api/v2/studies?query.cond=Hypopharyngeal+Cancer&filter.advanced=AREA%5BHasResults%5Dtrue&pageSize=1000&format=json&countTotal=true
source record id
Source null
source file sha256
cd92c144c33b33e75a38086ce6cbd6e62d34b7ba84c72dacac16e6781439e40e
payload sha256
2245f81ea8e2f584849c321a79e06c54a402a400ff484eb686508fde13fec416
payload
clinical indication matching status
condition_index_match_asserted_by_registry_not_reviewed
end exclusive
true
id
nct-edge-2206846920cc9860307e
link basis
returned_by_explicit_condition_and_posted_results_filter_query
nct id
NCT01816984
occurrences
context exact
NCT01816984
end
11
exact text
NCT01816984
start
0
offset unit
unicode_code_points
query cond
Hypopharyngeal Cancer
query disease state id
ds-hypopharyngeal-cancer
source file
/Users/arunverma/Documents/ChatGPT/Cancer Statistics Website/research-data/2026-09-10/clinicaltrials-condition/round-0000/raw/cond-hypopharyngeal-cancer-000.json
source file sha256
cd92c144c33b33e75a38086ce6cbd6e62d34b7ba84c72dacac16e6781439e40e
source json pointer
/studies/8/protocolSection/identificationModule/nctId
source kind
ctgov_condition_query
source record id
Source null
source string basis
parsed_JSON_string_unmodified
source string sha256
f0777abb7c3bc6e669446fda2e466119dbd18e0764c064a5cf4c6c4036a1fed8
source url
https://clinicaltrials.gov/api/v2/studies?query.cond=Hypopharyngeal+Cancer&filter.advanced=AREA%5BHasResults%5Dtrue&pageSize=1000&format=json&countTotal=true
release id
ctgov-registry-1336d216cbd1bbff780dac70
edge id
nct-edge-515010ce48f85ecbfa17
requested nct id
NCT01816984
primary nct id
NCT01816984
source kind
ctgov_condition_query
source url
https://clinicaltrials.gov/api/v2/studies?query.cond=Laryngeal+Cancer&filter.advanced=AREA%5BHasResults%5Dtrue&pageSize=1000&format=json&countTotal=true
source record id
Source null
source file sha256
fd31a95088dd8ee475e2862bffd724180f0c754cf3f0e892cba5b448df424980
payload sha256
c15b3200b9df857c7661a88f30aff0cb048896b3861a944b93e99bfb9635bb84
payload
clinical indication matching status
condition_index_match_asserted_by_registry_not_reviewed
end exclusive
true
id
nct-edge-515010ce48f85ecbfa17
link basis
returned_by_explicit_condition_and_posted_results_filter_query
nct id
NCT01816984
occurrences
context exact
NCT01816984
end
11
exact text
NCT01816984
start
0
offset unit
unicode_code_points
query cond
Laryngeal Cancer
query disease state id
ds-laryngeal-cancer
source file
/Users/arunverma/Documents/ChatGPT/Cancer Statistics Website/research-data/2026-09-10/clinicaltrials-condition/round-0000/raw/cond-laryngeal-cancer-000.json
source file sha256
fd31a95088dd8ee475e2862bffd724180f0c754cf3f0e892cba5b448df424980
source json pointer
/studies/15/protocolSection/identificationModule/nctId
source kind
ctgov_condition_query
source record id
Source null
source string basis
parsed_JSON_string_unmodified
source string sha256
f0777abb7c3bc6e669446fda2e466119dbd18e0764c064a5cf4c6c4036a1fed8
source url
https://clinicaltrials.gov/api/v2/studies?query.cond=Laryngeal+Cancer&filter.advanced=AREA%5BHasResults%5Dtrue&pageSize=1000&format=json&countTotal=true
release id
ctgov-registry-1336d216cbd1bbff780dac70
edge id
nct-edge-a6e5eb63c870e3c76f1b
requested nct id
NCT01816984
primary nct id
NCT01816984
source kind
ctgov_condition_query
source url
https://clinicaltrials.gov/api/v2/studies?query.cond=Metastatic+Squamous+Neck+Cancer+With+Occult+Primary&filter.advanced=AREA%5BHasResults%5Dtrue&pageSize=1000&format=json&countTotal=true
source record id
Source null
source file sha256
2598159af8c743c394b8ddc26022f84d68183b09edf878a8af96c931226e93a5
payload sha256
f3b80224acdcce6a4349bcb7cb38c0afd10fdef822a8606bbf70421744eeabf4
payload
clinical indication matching status
condition_index_match_asserted_by_registry_not_reviewed
end exclusive
true
id
nct-edge-a6e5eb63c870e3c76f1b
link basis
returned_by_explicit_condition_and_posted_results_filter_query
nct id
NCT01816984
occurrences
context exact
NCT01816984
end
11
exact text
NCT01816984
start
0
offset unit
unicode_code_points
query cond
Metastatic Squamous Neck Cancer With Occult Primary
query disease state id
ds-metastatic-squamous-neck-cancer-with-occult-primary
source file
/Users/arunverma/Documents/ChatGPT/Cancer Statistics Website/research-data/2026-09-10/clinicaltrials-condition/round-0000/raw/cond-metastatic-squamous-neck-cancer-with-occult-primary-000.json
source file sha256
2598159af8c743c394b8ddc26022f84d68183b09edf878a8af96c931226e93a5
source json pointer
/studies/3/protocolSection/identificationModule/nctId
source kind
ctgov_condition_query
source record id
Source null
source string basis
parsed_JSON_string_unmodified
source string sha256
f0777abb7c3bc6e669446fda2e466119dbd18e0764c064a5cf4c6c4036a1fed8
source url
https://clinicaltrials.gov/api/v2/studies?query.cond=Metastatic+Squamous+Neck+Cancer+With+Occult+Primary&filter.advanced=AREA%5BHasResults%5Dtrue&pageSize=1000&format=json&countTotal=true
release id
ctgov-registry-1336d216cbd1bbff780dac70
edge id
nct-edge-b1adc65ab76451a7e89e
requested nct id
NCT01816984
primary nct id
NCT01816984
source kind
ctgov_condition_query
source url
https://clinicaltrials.gov/api/v2/studies?query.cond=Salivary+Gland+Cancer&filter.advanced=AREA%5BHasResults%5Dtrue&pageSize=1000&format=json&countTotal=true
source record id
Source null
source file sha256
38e97f6c23d7b292911d062dea3fc0dffbdcbde03aae232fe8d067fdd28034c9
payload sha256
9168e15254b5d1b87b9ee99f9796797e1e1c7aa49843cd0f091b1192e9622e34
payload
clinical indication matching status
condition_index_match_asserted_by_registry_not_reviewed
end exclusive
true
id
nct-edge-b1adc65ab76451a7e89e
link basis
returned_by_explicit_condition_and_posted_results_filter_query
nct id
NCT01816984
occurrences
context exact
NCT01816984
end
11
exact text
NCT01816984
start
0
offset unit
unicode_code_points
query cond
Salivary Gland Cancer
query disease state id
ds-salivary-gland-cancer
source file
/Users/arunverma/Documents/ChatGPT/Cancer Statistics Website/research-data/2026-09-10/clinicaltrials-condition/round-0000/raw/cond-salivary-gland-cancer-000.json
source file sha256
38e97f6c23d7b292911d062dea3fc0dffbdcbde03aae232fe8d067fdd28034c9
source json pointer
/studies/5/protocolSection/identificationModule/nctId
source kind
ctgov_condition_query
source record id
Source null
source string basis
parsed_JSON_string_unmodified
source string sha256
f0777abb7c3bc6e669446fda2e466119dbd18e0764c064a5cf4c6c4036a1fed8
source url
https://clinicaltrials.gov/api/v2/studies?query.cond=Salivary+Gland+Cancer&filter.advanced=AREA%5BHasResults%5Dtrue&pageSize=1000&format=json&countTotal=true

Preserved source evidence · Not medical advice